ImmunityBio Inc (NASDAQ:IBRX) traded at $5.23 at close of the session on Monday, March 18, made an upward move of 1.95% on its previous day’s price.
Looking at the stock we see that its previous close was $5.13 and the beta (5Y monthly) reads 0.00 . In terms of its 52-week price range, IBRX has a high of $6.93 and a low of $1.25. The company’s stock has gained about 9.41% over that past 30 days.
ImmunityBio Inc has a market cap of $3.49 billion and is expected to release its quarterly earnings report on Mar 12, 2024 – Mar 16, 2024. Estimates by analysts give the company expected earnings per share (EPS) of -$0.18, with the EPS growth for the year raised at -$0.93 for 2023 and -$0.68 for next year. These figures represent 10.60% and 26.90% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $20k, with a low of $20k and a high of $20k. The median projection represents growth adding up to -72.60% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2023 is expected to hit $510k, or 112.50% up from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the IBRX stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Looking further, we note the current price level is 8.29% off its SMA20 and 21.08% from its 50-day simple moving average. The RSI (14) is pointing at 57.31 while the volatility over the past week is 6.55% and jumps to 11.53% over the past one month. The beta value is 1.09, while the average true range (ATR) is currently pointing at 0.44.
Coming back to ImmunityBio Inc (NASDAQ:IBRX), we note that the average 3-month trading volume was 3.96 million, while that of the preceding 10-day period stands at 3.89 million. Current shares outstanding are 421.57 million.
The insiders hold 80.43% of the company’s shares while institutions hold 8.57%. The data shows that short shares as of Feb 29, 2024, stood at 51.55 million at a short ratio of 11.49. This represents a 7.69% short interest in shares outstanding on Feb 29, 2024. Shares short rose in February from the previous month at 43.93 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 4.18% up in year-to-date price movement.
